-+ 0.00%
-+ 0.00%
-+ 0.00%

Medivir Q3 Operating Loss Widens 26% to SEK 17.1 Million

PUBT·11/05/2026 07:52:32
Listen to the news
Medivir Q3 Operating Loss Widens 26% to SEK 17.1 Million
  • Medivir’s third-quarter 2026 operating loss widened 26% year over year to SEK 17.1 million due to higher clinical study costs.
  • Net sales fell 22% year over year to SEK 700,000 due to lower royalty income.
  • Quarter-end cash and short-term investments rose year over year to SEK 247.9 million.
  • Patient recruitment in FLEX-HCC remained on track, while preparations progressed for MIV-711 proof-of-concept studies in two rare bone diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medivir AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.